Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid versus Lianhua Qingwen for shortening SARS-CoV-2 nucleic acid negative conversion time
ChiCTR2200059739Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Nirmatrelvir and Lianhua Qingwen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Renji Hospital. Primary endpoints: Nucleic acid negative conversion time and Nucleic acid negative conversion rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
NirmatrelvirLianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200059739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059739.